Literature DB >> 30291792

Toward the potential cure of leukemias in the next decade.

Hagop M Kantarjian1, Michael J Keating1, Emil J Freireich1.   

Abstract

Historically, progress in leukemia research has been slow, but it has accelerated recently as a result of understanding the pathophysiology of leukemias and implementing more effective and targeted therapies. This review summarizes the progress across leukemia subsets and projects the potential cure of most leukemias in the next decade.
© 2018 American Cancer Society.

Entities:  

Keywords:  cure; leukemias; targeted; therapy; treatments

Mesh：

Substances：

Year:  2018        PMID： 30291792     DOI： 10.1002/cncr.31669

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  10 in total

1.  Is Precision Medicine Consistent With Primary Care?

Authors:  Dana E King
Journal:  Fam Med       Date:  2019-03       Impact factor: 1.756

Review 2.  The cure of leukemia through the optimist's prism.

Authors:  Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour
Journal:  Cancer       Date:  2021-10-06       Impact factor: 6.860

3.  LncRNA UCA1 elevates the resistance of human leukemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613.

Authors:  Qiying Yao; Li Zhang; Yuchuan Wang; Junli Liu; Liu Yang; Yingjie Wang
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

4.  Leukemia incidence trends at the global, regional, and national level between 1990 and 2017.

Authors:  Ying Dong; Oumin Shi; Quanxiang Zeng; Xiaoqin Lu; Wei Wang; Yong Li; Qi Wang
Journal:  Exp Hematol Oncol       Date:  2020-06-19

5.  Identification of two downregulated circRNAs in patients with acute B-lymphocytic leukemia.

Authors:  Bo Zhou; Liansheng Zhong; Liu Tian; Ye Zhang; Runan Wang; Qun He; Yujie Zhao
Journal:  Oncol Lett       Date:  2021-12-03       Impact factor: 2.967

6.  Small molecule MMRi62 targets MDM4 for degradation and induces leukemic cell apoptosis regardless of p53 status.

Authors:  Rati Lama; Chao Xu; Samuel L Galster; Javier Querol-García; Scott Portwood; Cory K Mavis; Federico M Ruiz; Diana Martin; Jin Wu; Marianna C Giorgi; Jill Bargonetti; Eunice S Wang; Francisco J Hernandez-Ilizaliturri; Gerald B Koudelka; Sherry R Chemler; Inés G Muñoz; Xinjiang Wang
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

7.  Synthesis and Antileukemia Activity Evaluation of Benzophenanthridine Alkaloid Derivatives.

Authors:  Yaling Tang; Xinglian Xu; Jiang Li; Lulu Deng; Shuzhen Mu
Journal:  Molecules       Date:  2022-06-19       Impact factor: 4.927

8.  Cephalotaxine Inhibits the Survival of Leukemia Cells by Activating Mitochondrial Apoptosis Pathway and Inhibiting Autophagy Flow.

Authors:  Tingting Liu; Qiang Guo; Shuze Zheng; Yang Liu; Heng Yang; Meimei Zhao; Lu Yao; Kewu Zeng; Pengfei Tu
Journal:  Molecules       Date:  2021-05-18       Impact factor: 4.411

9.  Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.

Authors:  Almudena Aguilera-Diaz; Iria Vazquez; Beñat Ariceta; Amagoia Mañú; Zuriñe Blasco-Iturri; Sara Palomino-Echeverría; María José Larrayoz; Ramón García-Sanz; María Isabel Prieto-Conde; María Del Carmen Chillón; Ana Alfonso-Pierola; Felipe Prosper; Marta Fernandez-Mercado; María José Calasanz
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

10.  Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling.

Authors:  Jiang Yu; Wen-Xu Chen; Wen-Jing Xie; Rong-Wei Chen; Dan-Qi Lin; Wei-Wei You; Wei-Lin Ye; Hong-Qin Zhang; Dong-Hong Lin; Jian-Ping Xu
Journal:  J Clin Lab Anal       Date:  2021-06-11       Impact factor: 2.352
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.